share_log

Wedbush's Dan Ives Equates Nvidia's Market Stature To Lebron James' Early Career

Benzinga ·  Sep 1 22:31

Wedbush analyst Dan Ives has drawn a parallel between the market dominance of Nvidia Corp. (NASDAQ:NVDA) and the prowess of a young LeBron James.

What Happened: Last week, Ives reiterated his bullish outlook on Nvidia, drawing a comparison to one of the greatest basketball players in history.

Ives told Bloomberg, "If you look at Nvidia here, this is LeBron in high school in terms of where this story is ultimately going."

Ives further emphasized Nvidia's lead over its competitors, referring to it as "the only game in town." Despite the concerns regarding the delay of the upcoming Blackwell chips, Ives lauded Nvidia's strong revenue guidance.

According to Fortune, he also underscored the multiplier effect that Nvidia has on the tech sector, explaining that every dollar spent on its chips echoes through the industry by a factor of 8-10 times.

Also Read: Mark Cuban's NBA Strategy for Klay Thompson With Mavericks: 'Obviously The Big Addition Was Klay, Hopefully His Life Is Going To Be A Lot Easier'

Ives anticipates $1 trillion of capital expenditures on AI over the next three years, which is double his forecast from six months ago.

Even though Nvidia's stock suffered an 8% weekly loss, most Wall Street analysts, including those at Bank of America Global Research, continue to maintain a "buy" rating on Nvidia shares.

Why It Matters: Given the absence of context articles, the significance of this news can be inferred from the information provided. Nvidia's comparison to a young LeBron James underscores the company's potential and its unrivaled position in the tech industry.

The anticipated capital expenditures on AI and the multiplier effect of Nvidia's chips indicate a promising future for the company, despite short-term stock fluctuations.

Read Next

Nvidia CEO Jensen Huang Identifies $1 Trillion Opportunity Amid Generative AI Shift: 'Data Centers Will Be All Accelerated Computing'

This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment